share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Schuyler Kevin

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4:持股变动声明
美股SEC公告 ·  03/28 06:10

Moomoo AI 已提取核心信息

In a recent transaction dated 03/25/2024, Schuyler Kevin engaged in a stock market activity involving Adial Pharmaceuticals, Inc. (ADIL). The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the resulting total value of shares held by Schuyler Kevin after the action, have not been disclosed. The relationship of Schuyler Kevin to the issuer, Adial Pharmaceuticals, was not specified in the announcement.
In a recent transaction dated 03/25/2024, Schuyler Kevin engaged in a stock market activity involving Adial Pharmaceuticals, Inc. (ADIL). The specific details of the transaction, including the number of shares traded, the nature of the shares, the transaction price, and the resulting total value of shares held by Schuyler Kevin after the action, have not been disclosed. The relationship of Schuyler Kevin to the issuer, Adial Pharmaceuticals, was not specified in the announcement.
在最近于2024年3月25日的一笔交易中,舒勒·凯文参与了涉及阿迪尔制药公司(ADIL)的股票市场活动。该交易的具体细节,包括交易的股票数量、股票的性质、交易价格以及舒勒·凯文在诉讼后持有的股票的总价值,尚未披露。公告中没有具体说明舒勒·凯文与发行人阿迪亚尔制药的关系。
在最近于2024年3月25日的一笔交易中,舒勒·凯文参与了涉及阿迪尔制药公司(ADIL)的股票市场活动。该交易的具体细节,包括交易的股票数量、股票的性质、交易价格以及舒勒·凯文在诉讼后持有的股票的总价值,尚未披露。公告中没有具体说明舒勒·凯文与发行人阿迪亚尔制药的关系。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息